Literature DB >> 11718500

Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis.

S D Ross1, K S Akhras, S Zhang, M Rozinsky, L Nalysnyk.   

Abstract

We conducted a systematic review of randomized, controlled, monotherapy trials since 1990 of oral antihypertensive agents in patients with essential hypertension. Our objective was to quantify the frequency of discontinuation of antihypertensive agents due to adverse events from a meta-analysis of the studies. A total of 190 studies met inclusion criteria. The highest frequency of discontinuations due to adverse events (DAEs) occurred with calcium channel blockers (6.7%) and alpha-adrenergic blockers (6.0%); the lowest with diuretics and angiotensin receptor blockers (each 3.1%). Only in calcium channel blocker studies was the frequency of DAEs greater in treated patients than in patients receiving placebo, but the difference was not significant. This systematic review suggests that the frequency of DAEs in monotherapy antihypertensive trials varies across drug classes and should be considered when choosing drugs for patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718500     DOI: 10.1592/phco.21.11.940.34520

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  26 in total

1.  Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Multiple drug-intolerant hypertension: a case series utilising a novel-treatment algorithm.

Authors:  Manish Saxena; Sotiris Antoniou; Nadya Hamedi; Paul Robinson; Harjit Singh; Omar Mukhtar; Vikas Kapil; Melvin D Lobo
Journal:  Br J Gen Pract       Date:  2016-04       Impact factor: 5.386

Review 3.  Desirable therapeutic characteristics of an optimal antihypertensive agent.

Authors:  Lisa Mustone Alexander
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus.

Authors:  Justin W Timbie; Rodney A Hayward; Sandeep Vijan
Journal:  Arch Intern Med       Date:  2010-06-28

Review 5.  Managing kidney disease with blood-pressure control.

Authors:  Elke Wühl; Franz Schaefer
Journal:  Nat Rev Nephrol       Date:  2011-06-21       Impact factor: 28.314

6.  Effect of self-efficacy and social support on adherence to antihypertensive drugs.

Authors:  Thomas J Criswell; Cynthia A Weber; Yinghui Xu; Barry L Carter
Journal:  Pharmacotherapy       Date:  2010-05       Impact factor: 4.705

7.  Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes.

Authors:  Justin W Timbie; Rodney A Hayward; Sandeep Vijan
Journal:  Health Serv Res       Date:  2010-01-08       Impact factor: 3.402

Review 8.  Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.

Authors:  David H G Smith
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting.

Authors:  Carla B C Gonçalves; Leila B Moreira; Miguel Gus; Flávio D Fuchs
Journal:  Eur J Clin Pharmacol       Date:  2007-08-11       Impact factor: 2.953

10.  Reduction in adverse symptoms as blood pressure becomes controlled.

Authors:  Cynthia A Weber; Megan R Leloux; Barry L Carter; Karen B Farris; Yinghui Xu
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.